J
Joseph R. Mace
Researcher at Sarah Cannon Research Institute
Publications - 22
Citations - 1141
Joseph R. Mace is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Population & Carfilzomib. The author has an hindex of 9, co-authored 21 publications receiving 778 citations. Previous affiliations of Joseph R. Mace include University of Michigan.
Papers
More filters
Journal ArticleDOI
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Thierry Facon,Shaji Kumar,Torben Plesner,Robert Z. Orlowski,Philippe Moreau,Nizar J. Bahlis,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Michael O'Dwyer,Aurore Perrot,Christopher P. Venner,Katja Weisel,Joseph R. Mace,Noopur Raje,Michel Attal,Mourad Tiab,Margaret Macro,Laurent Frenzel,Xavier Leleu,Tahamtan Ahmadi,Christopher Chiu,Jianping Wang,Rian Van Rampelbergh,Clarissa M. Uhlar,Rachel Kobos,Ming Qi,Saad Z. Usmani,Maia Trial Investigators +30 more
TL;DR: Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among thosewho received lenalidmide and Dexameth asone alone.
Journal ArticleDOI
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Thierry Facon,Shaji Kumar,Torben Plesner,Robert Z. Orlowski,Philippe Moreau,Nizar J. Bahlis,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Michael O'Dwyer,Aurore Perrot,Christopher P. Venner,Katja Weisel,Joseph R. Mace,Noopur Raje,Mourad Tiab,Margaret Macro,Laurent Frenzel,Xavier Leleu,Tahamtan Ahmadi,Jianping Wang,Rian Van Rampelbergh,Clarissa M. Uhlar,Brenda Tromp,Maria Delioukina,Jessica Vermeulen,Saad Z. Usmani +28 more
TL;DR: In the MAIA trial as discussed by the authors, a significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone.
Journal ArticleDOI
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
Jesus G. Berdeja,Lowell L. Hart,Joseph R. Mace,Edward Arrowsmith,James Essell,Rami Owera,John D. Hainsworth,Ian W. Flinn +7 more
TL;DR: The combination of panobinostat and carfilzomib is feasible and effective in patients with relapsed/refractory multiple myeloma and at a median follow up of 17 months, median progression-free survival was 7.7 years, median time to progression was 7 months, and median overall survival had not been reached.
Journal ArticleDOI
Phase II Study of 9-Nitro-Camptothecin in Patients With Advanced Chordoma or Soft Tissue Sarcoma
Rashmi Chugh,Rodney L. Dunn,Mark M. Zalupski,J. Sybil Biermann,Vernon K. Sondak,Joseph R. Mace,Kirsten M. Leu,William F. Chandler,Laurence H. Baker +8 more
TL;DR: 9-NC is associated with moderate toxicity and shows little benefit in patients with advanced STS and GIST and has modest activity in delaying progression in Patients with unresectable or metastatic chordoma.
Journal ArticleDOI
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Guillermo Garcia-Manero,Gail J. Roboz,Katherine Walsh,Hagop M. Kantarjian,Ellen K. Ritchie,Patricia Kropf,Casey O'Connell,Raoul Tibes,Scott D. Lunin,Todd L. Rosenblat,Karen Yee,Wendy Stock,Elizabeth A. Griffiths,Joseph R. Mace,Nikolai A. Podoltsev,Jesus G. Berdeja,Elias Jabbour,Jean Pierre J. Issa,Yong Hao,Harold N. Keer,Mohammad Azab,Michael R. Savona +21 more
TL;DR: The activity and safety of two doses of guadecitabine in hypomethylating agent treatment-naive or relapsed or refractory patients with intermediate-risk or high-risk myelodysplastic syndromes are compared.